Psoriatic Arthritis - Global Clinical Trials Review and Competitive Landscape, 2026 | Pipeline Innovation and Trial Expansion Drive Strategic Growth

Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy.

Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Psoriatic Arthritis - Global Clinical Trials Review, 2026" has been added to ResearchAndMarkets.com's offering.

The 2026 report delivers a comprehensive assessment of the global Psoriatic Arthritis clinical trials landscape, providing top line data on trial activity, patient enrollment and research trends. Its analysis covers clinical trials by region, country, phase, trial status, end point status and sponsor type, enabling pharmaceutical companies, biotechnology firms, investors and clinical research organizations to evaluate developments across the Psoriatic Arthritis therapeutics market.

Global and country-level coverage includes major G7 and E7 markets, with data on trial numbers and average enrollment across leading research locations. The report also examines enrollment trends over the past five years, helping stakeholders assess changes in patient recruitment, geographic participation and clinical development activity. By comparing trial counts and enrollment patterns across countries, organizations can identify prominent locations for future Psoriatic Arthritis clinical trials while considering potential time and cost efficiencies.

The report reviews the leading companies involved in Psoriatic Arthritis research and lists relevant studies by trial title, phase and status. It also identifies prominent drugs featured in in-progress trials based on the number of ongoing studies. This information supports competitive intelligence, portfolio analysis and the evaluation of emerging opportunities within the global Psoriatic Arthritis treatment pipeline.

Coverage extends across completed and unaccomplished studies, including terminated, suspended and withdrawn trials. Reasons for unaccomplishment are provided where available, allowing users to compare successful and unsuccessful clinical development activity. This comparative perspective can assist with risk assessment, trial planning and the interpretation of clinical trial success rates across global, regional and country-level markets.

The analysis is generated from the analyst's proprietary Pharma - Clinical trials database. Clinical trial information is collated from more than 80 registries and additional sources worldwide, including conferences, journals and news publications. The database is updated periodically through a dynamic process to support access to relevant clinical research information. The report also includes recent Psoriatic Arthritis clinical trial news from the past three months, offering additional insight into current industry developments.

Report Scope

• Provides a snapshot of the global Psoriatic Arthritis clinical trials landscape.
• Analyzes clinical trials by region, G7 and E7 country, trial phase, trial status, sponsor type and end point status.
• Presents trial counts and average enrollment data for leading countries worldwide.
• Reviews major participating companies and lists associated trials by title, phase and status.
• Highlights prominent drugs in in-progress studies based on ongoing trial volume.
• Examines terminated, suspended and withdrawn trials, including available reasons for unaccomplishment.
• Tracks clinical trial enrollment trends over the past five years.
• Summarizes relevant industry news published during the past three months.

Business Value

• Supports strategic investment and clinical development planning in the Psoriatic Arthritis market.
• Helps identify key countries and regions for conducting clinical trials.
• Enables analysis of global clinical trial activity and potential business opportunities.
• Strengthens understanding of country-specific trial counts and patient enrollment trends.
• Supports comparison of completed and uncompleted trials for informed risk evaluation.
• Facilitates assessment of Psoriatic Arthritis clinical research at global, regional and country levels.
• Enhances competitive intelligence by identifying leading sponsors, active studies and prominent pipeline drugs.

Note: Certain sections may be removed or adjusted depending on the availability and relevance of data for Psoriatic Arthritis.

Key Topics Covered:

• Report Guidance
• The analyst Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Psoriatic Arthritis to Musculoskeletal Disorders Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Psoriatic Arthritis Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Psoriatic Arthritis
• Feb 20, 2026: O3R-5671 Pharmacokinetic and Pharmacodynamic Data Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
• Jan 12, 2026: Oruka Therapeutics Announces Initiation of EVERLAST-B Trial of ORKA-001
• Jan 09, 2026: Eli Lilly's Taltz-Zepbound combo scores in late-stage PsA study
• Jan 08, 2026: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
• Dec 03, 2025: Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 Inhibitor O3R-5671
• Clinical Trial Profile Snapshots
• Appendix
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About the Analyst
• Contact the Publisher
• Source

List of Tables [23]

List of Figures [24]

A selection of companies mentioned in this report includes, but is not limited to:

• Abbvie Inc
• Johnson & Johnson
• Amgen
• Pfizer
• Novartis AG
• UCB SA
• Bristol-Myers Squibb
• Icon Plc
• Labcorp Holdings Inc
• Thermo Fisher Scientific

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/9dazw4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900